Flow-mediated dilatation

Citation
Ot. Raitakari et Ds. Celermajer, Flow-mediated dilatation, BR J CL PH, 50(5), 2000, pp. 397-404
Citations number
64
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
ISSN journal
0306-5251 → ACNP
Volume
50
Issue
5
Year of publication
2000
Pages
397 - 404
Database
ISI
SICI code
0306-5251(200011)50:5<397:FD>2.0.ZU;2-#
Abstract
Arterial endothelial dysfunction is one of the key early events in atheroge nesis, preceding structural atherosclerotic changes. It is also important i n the late stages of obstructive atherosclerosis, predisposing to constrict ion and/or thrombosis. Endothelial function can be measured in coronary art eries and in the periphery by measuring vasomotor function after intra-arte rial infusion of pharmacologic substances which enhance the release of endo thelial nitric oxide. The disadvantage of these methods is their invasive n ature, which generally makes them unsuitable for studies involving asymptom atic subjects. For this reason, noninvasive tests of endothelial function h ave been developed. In the most widely used of these, an ultrasound-based m ethod, arterial diameter is measured in response to an increase in shear st ress, which causes endothelium-dependent dilatation. Endothelial function a ssessed by this method correlates with invasive testing of coronary endothe lial function, as well as with the severity and extent of coronary atherosc lerosis. This noninvasive endothelial function testing has provided valuabl e insights into early atherogenesis, as well as into the potential reversib ility of endothelial dysfunction by various strategies, including pharmacol ogical agents (lipid lowering, ACE inhibition), l-arginine, antioxidants an d hormones.